| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.051 | 0.3 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |